ABL Diagnostics Demonstrates Unique DeepChek® Technology Across All NGS Platforms in Breakthrough Study
WOIPPY, FRANCE, September 3, 2025 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, today announced the results of a new peer-reviewed study published in LabMed (Martinez et al …